TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8487239
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (sequential and continuous)
Study: 3302998
Drug: Piroxicam, 20
Normalized name: Piroxicam, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam, 20 mg daily, orally for 10 days
Study: 29227377
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg and Amiloride 2.5 mg once a day
Study: 17888078
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (60-min infusions)
Study: 17888078
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide (30-min infusions)
Study: 17888078
Drug: Oral lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lacosamide (control)
Study: 12538372
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 20 mg bd i.v.
Study: 12538372
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg bd i.v.
Study: 11515622
Drug: One-week treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Study: 11515622
Drug: Two-week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Study: 8890678
Drug: Diazepam (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (intravenous doses)
Study: 6452796
Drug: Zimelidine (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (225 mg)
Study: 6225313
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg)
Study: 29551533
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (7 DU)
Study: 29551533
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (all doses)
Study: 26951571
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of directly observed once‐weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP‐DOT)
Study: 26951571
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of daily self‐administered isoniazid (maximum dose, 300 mg; 9H‐SAT)
Study: 21602517
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of ketoconazole (a potent CYP3A4 inhibitor)
Study: 21602517
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of erythromycin (a moderate CYP3A4 inhibitor)
Study: 21602517
Drug: Ruxolitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib alone and in combination with ketoconazole, erythromycin, or rifampin
Study: 15470331
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (300 mg 3 times daily)
Study: 11394559
Drug: Self‐administered, computer‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered, computer‐based intervention delivered in 15 brief weekly segments
Study: 11394559
Drug: Self‐administered, computer‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered, computer‐based intervention
Study: 11547642
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 gel
Study: 8066102
Drug: Single intracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intracervical application of PGE2 gel
Study: 8066102
Drug: Repeated intracervical
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intracervical application of PGE2 gel (2 h apart)
Study: 2713518
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM), loco-regional radiotherapy and maintenance chemotherapy with vincristine, cyclophosphamide and 5 fluorouracil (VCF)
Study: 2713518
Drug: Reinforced protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced protocol with five drugs: adriamycin, vincristine, cyclophosphamide, methotrexate, 5 FU (AVCMF)
Study: 2713518
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM)
Study: 30209576
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a plasma concentration of 1000 ng/mL
Study: 30209576
Drug: Propofol 20
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 20 mg as a rescue antiemetic
Study: 25904602
Drug: DBP concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBP concentration (highest quintile ≥7149.4 nmol/L)
Study: 25904602
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D (highest group ≥100 nmol/L)
Study: 25904602
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D (lowest group <25 nmol/L)
Study: 16980806
Drug: Daily infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infant massage therapy by orphanage staff or volunteers for an average of 53 days
Study: 14626640
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and micronutrient combination supplementation (including vitamin B12 and B6)
Study: 8797135
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg oral dose)
Study: 8797135
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg oral dose)
Study: 6241770
Drug: 20 ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ng hepatitis B surface antigen aluminium‐adsorbed vaccine, 3 doses of 40 micrograms over 6 months
Study: 6241770
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine prior to surgery
Study: 31190122
Drug: Baseline PTH
Normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PTH of 0 pg/mL
Study: 31190122
Drug: Baseline PTH
Normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PTH of 69 pg/mL
Study: 31190122
Drug: Baseline PTH
Normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PTH of 58 pg/mL
Study: 18514105
Drug: OMS103HP (investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS103HP (investigational drug product containing ketoprofen, amitriptyline, and oxymetazoline)
Study: 12032039
Drug: Propofol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.2 mg/kg followed by infusion at a rate of 2 mg.kg(‐1).h(‐1)
Study: 12032039
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam 5 mg
Study: 9706861
Drug: 25% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% metronidazole sustained release gel
Study: 9706861
Drug: 3% tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% tetracycline ointment
Study: 23137
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of aspirin
Study: 21921285
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with tamoxifen (20 mg/d for 5 years)
Study: 21921285
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with tamoxifen (20 mg/d for 5 years)
Study: 21921285
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with tamoxifen
Study: 21921285
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with tamoxifen
Study: 17245184
Drug: I methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I methylene blue (various doses)
Study: 29992150
Drug: 2% Chamaemelum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Chamaemelum nobile gel
Study: 27401569
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) monthly for 1 year
Study: 17825129
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER (300 mg once daily for patients ≥ 75 years; 300-400 mg once daily for patients < 75 years)
Study: 17825129
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER (open-label treatment after placebo-controlled studies)
Study: 1941057
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy (group A, 105 patients)
Study: 1941057
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (AC6, 23 patients)
Study: 1941057
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy at 3-month intervals for 1 year (AC10, 26 patients)
Study: 1941057
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (MOPP + radiation)
Study: 24664227
Drug: 1200 mg/d
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/d of CoQ10
Study: 24664227
Drug: 2400 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/d of CoQ10
Study: 21849198
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml polidocanol sclerotherapy (30 mg/ml)
Study: 21849198
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml polidocanol sclerotherapy (30 mg/ml)
Study: 21849198
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (1 to 4 treatments)
Study: 21849198
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Study: 21849198
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Study: 19463396
Drug: Guideline-recommended medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-recommended medications at 1 year (including aspirin, clopidogrel, ACE inhibitors, and statins)
Study: 17462482
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of interstitial cystitis (IC) in males
Study: 17462482
Drug: Diagnosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis and treatment of chronic nonbacterial prostatitis (CP)
Study: 9264419
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg twice daily
Study: 29957715
Drug: Intervention Phase
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention Phase I (focused education program and implementation of treatment bundle)
Study: 29957715
Drug: Intervention Phase
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention Phase II (provision of resources to implement treatment bundle)
Study: 26431823
Drug: Low-dose rAAV.sFLT-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rAAV.sFLT-1 (1×10^10 vector genomes)
Study: 26431823
Drug: High-dose rAAV.sFLT-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rAAV.sFLT-1 (1×10^11 vector genomes)
Study: 26431823
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gene therapy treatment)
Study: 14579214
Drug: Intracoronary nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicardipine (0.1 mg)
Study: 7512402
Drug: Intraprostatic spiral
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic spiral treatment
Study: 3279023
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day trimipramine
Study: 3279023
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day trimipramine
Study: 30037045
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of mixed spices
Study: 28301619
Drug: HBP Lotion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBP Lotion, 0.05% applied twice daily for 14 days
Study: 20731686
Drug: Aprotinin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (280 mg load + 70 mg/hL) administered during donor lung perfusion and peri-operatively to recipients
Study: 20731686
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during donor lung perfusion and peri-operatively to recipients
Study: 8828369
Drug: Aprotinin administration
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin administration
Study: 17003096
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment 1 mg/m2.d
Study: 9181901
Drug: Urolase fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urolase fiber (Bard) at 60 Watts for 60 seconds, administered to each lobe at 2, 4, 8 and 10 o'clock positions.
Study: 30685874
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg daily starting 3 weeks pre-operatively, continued for 1 week after surgical haemostasis)
Study: 30685874
Drug: IVIG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1 to 2 g/kg administered 1 week pre-operatively, with allowance for a second dose within 1 week after surgical haemostasis)
Study: 15956010
Drug: Prednisolone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (7.5 mg/d for 2 years)
Study: 12540786
Drug: Nadolol plus
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol plus spironolactone 100 mg/d (N + S)
Study: 1705938
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (morphine group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Duramorph (morphine sulphate), 0.5 mg
Study: 1705938
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (Dilaudid group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Dilaudid (hydromorphone hydrochloride), 0.002 mg/kg
Study: 6220729
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and hyoscine 0.4 mg
Study: 6220729
Drug: Papaveretum 20
Normalized name: papaveretum 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 20 mg and hyoscine 0.4 mg
Study: 6220729
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg and papaveretum 20 mg
Study: 26418044
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for APD (control group)
Study: 25085020
Drug: Fennel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel (30 mg) soft capsule every 4 hours, 3 days before menstruation until the 5th day for 3 months
Study: 19237093
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), doxycycline 100 mg (b.i.d.)
Study: 19237093
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), tetracycline 500 mg (q.i.d.)
Study: 15356061
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg)
Study: 7302369
Drug: Glipizide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (5 mg)
Study: 8087788
Drug: Androgen withdrawal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen withdrawal, androgen blockade, or combination therapy (first-line treatment modalities)
Study: 2659995
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream containing epidermal growth factor (10 micrograms per milliliter)
Study: 31290550
Drug: Web-based cessation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cessation treatment for SM smokers
Study: 31290550
Drug: Web-based cessation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cessation treatment for bisexual smokers
Study: 31228618
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) plus pharmacotherapy
Study: 26074287
Drug: wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: wound infiltration with 15 ml of ropivacaine 10%
Study: 18930987
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg) administered intravenously at weeks 0, 2, 6, and every 8 weeks thereafter to week 54
Study: 14568836
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with topical 20% 5‐aminolevulinic acid for 3 hours or 14 to 18 hours followed by LP PDL irradiation at 595 nm
Study: 10969448
Drug: Miacalcic (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miacalcic (100 IU dose, intramuscularly)
Study: 10969448
Drug: Calcinin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcinin (100 IU dose, intramuscularly)
Study: 2578716
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen PUVA
Study: 28645636
Drug: Theobromine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (500 mg/day)
Study: 28383633
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m2 for patients <70 years; 1000 mg/m2 for patients ≥70 years, twice daily on days 1-14)
Study: 28383633
Drug: S-1 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (30 mg/m2 orally twice daily on days 1-14)
Study: 26358345
Drug: Nasal triamcinolone
Normalized name: triamcinolone Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal triamcinolone acetonide 220 μg once daily for 28 days
Study: 21884606
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vitamin A supplementation (VAS)
Study: 21884606
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose vitamin A supplementation (VAS)
Study: 19994681
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (oral administration of Diethylstilbestrol tablet)
Study: 17900050
Drug: ECT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT treatment (bitemporal ECT 3 times a week)
Study: 17900050
Drug: Imipramine or
Normalized name: imipramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine or desipramine (150-250 mg/day)
Study: 16395953
Drug: ECT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT treatment
Study: 11951995
Drug: New formula
Normalized name: Correct (New Formula)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formula (<0.1 mg Fe 100 ml(‐1))
Study: 11951995
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (0.5 mg Fe 100 ml(‐1))
Study: 9849711
Drug: Extra-amniotic balloon
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic balloon with intracervical PGE2 (0.5 mg x 2)
Study: 9849711
Drug: Extra-ovular Foley
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-ovular Foley catheter with intrauterine PGF2alpha (1 mg/h x 6)
Study: 7746297
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg b.i.d. for 4 weeks
Study: 7746297
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg once-daily for 4 weeks
Study: 2563963
Drug: Nonenteric coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonenteric coated pancreatic enzyme supplement without ranitidine
Study: 2563963
Drug: Nonenteric coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonenteric coated pancreatic enzyme supplement with ranitidine
Study: 2563963
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated pancreatic enzyme supplements
Study: 30735435
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with pembrolizumab
Study: 29389742
Drug: Control (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (discontinue all antihypertensive medications)